What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Breast cancer
His primary scientific interests are in Internal medicine, Breast cancer, Oncology, Tamoxifen and Chemotherapy.
His work on Internal medicine deals in particular with Cancer, Randomized controlled trial, Clinical trial, Survival analysis and Disease.
His Breast cancer research is multidisciplinary, relying on both Chemotherapy regimen, Radiation therapy, Surgery, Hazard ratio and Adjuvant therapy.
The various areas that he examines in his Oncology study include Metastatic breast cancer, Mammary gland, Gynecology, Estrogen receptor and Mastectomy.
Alan S. Coates studied Tamoxifen and Tolerability that intersect with Median follow-up.
His Chemotherapy research includes themes of Survival rate, Adjuvant, Incidence and Meta-analysis.
His most cited work include:
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2308 citations)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
- A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer. (1568 citations)
What are the main themes of his work throughout his whole career to date?
Alan S. Coates mostly deals with Internal medicine, Breast cancer, Oncology, Tamoxifen and Chemotherapy.
His research in Internal medicine intersects with topics in Gynecology and Surgery.
He combines subjects such as Clinical trial, Adjuvant therapy and Hazard ratio with his study of Breast cancer.
His Oncology research focuses on Disease and how it relates to Systemic therapy.
His Tamoxifen study combines topics in areas such as Aromatase and Cohort.
His study in Chemotherapy is interdisciplinary in nature, drawing from both Mastectomy, Methotrexate, Randomization and Mammary gland.
He most often published in these fields:
- Internal medicine (91.67%)
- Breast cancer (72.33%)
- Oncology (73.67%)
What were the highlights of his more recent work (between 2013-2021)?
- Internal medicine (91.67%)
- Breast cancer (72.33%)
- Oncology (73.67%)
In recent papers he was focusing on the following fields of study:
Alan S. Coates mainly investigates Internal medicine, Breast cancer, Oncology, Tamoxifen and Exemestane.
Alan S. Coates combines topics linked to Gynecology with his work on Internal medicine.
Alan S. Coates has included themes like Surgery, Proportional hazards model, Clinical trial and Hazard ratio in his Breast cancer study.
His Hazard ratio study combines topics from a wide range of disciplines, such as Survival rate and Prospective cohort study.
His Oncology research is multidisciplinary, incorporating perspectives in Randomization, Hormone receptor, Adjuvant therapy and Endocrine system.
Alan S. Coates interconnects Aromatase, Quality of life and Cohort in the investigation of issues within Tamoxifen.
Between 2013 and 2021, his most popular works were:
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (982 citations)
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer (445 citations)
- Adjuvant ovarian suppression in premenopausal breast cancer (418 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Tamoxifen and Chemotherapy.
His work is connected to Proportional hazards model, Radiation therapy and Disease, as a part of Internal medicine.
His work carried out in the field of Breast cancer brings together such families of science as Survival rate, Surgery, Clinical endpoint and Hazard ratio.
Alan S. Coates regularly ties together related areas like Adverse effect in his Oncology studies.
His Tamoxifen research is multidisciplinary, incorporating elements of Randomized controlled trial, Quality of life and Endocrine system.
The study incorporates disciplines such as Meta-analysis and Anthracycline in addition to Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
